Adagene Inc. – NASDAQ:ADAG
Adagene stock price today
$1.92
-0.04
-2.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Adagene stock price monthly change
-28.99%
month
Adagene stock price quarterly change
-28.99%
quarter
Adagene stock price yearly change
+18.07%
year
Adagene key metrics
Market Cap | 84.55M |
Enterprise value | N/A |
P/E | -0.67 |
EV/Sales | -105.81 |
EV/EBITDA | 3.27 |
Price/Sales | 67.50 |
Price/Book | 0.52 |
PEG ratio | N/A |
EPS | -0.65 |
Revenue | 27.18M |
EBITDA | -28.84M |
Income | -28.73M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -3307.95% |
Oper. margin | -3350.58% |
Gross margin | 0% |
EBIT margin | -3350.58% |
EBITDA margin | -106.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAdagene stock price history
Adagene stock forecast
Adagene financial statements
| Mar 2023 | 8.64M | -2.05M | -23.76% |
|---|---|---|---|
| Jun 2023 | 17.29M | -4.10M | -23.76% |
| Sep 2023 | 407.87K | -7.41M | -1818.9% |
| Dec 2023 | 833.33K | -15.15M | -1818.9% |
| 2025 | 9M | -80.79M | -897.73% |
|---|---|---|---|
| 2026 | 19.16M | -104.18M | -543.68% |
| 2027 | 44.29M | -37.65M | -85.02% |
| 2028 | 122.45M | -12.26M | -10.01% |
Analysts Price target
Financials & Ratios estimates
| 2021-03-31 | -0.4 | -1.55 |
|---|---|---|
| 2023-03-28 | -0.4 | -1.55 |
| Mar 2023 | 135302264 | 52.50M | 38.81% |
|---|---|---|---|
| Jun 2023 | 135302264 | 52.50M | 38.81% |
| Sep 2023 | 115728838 | 45.16M | 39.03% |
| Dec 2023 | 115728838 | 45.16M | 39.03% |
| Mar 2023 | 2.01M | 0 | 0 |
|---|---|---|---|
| Jun 2023 | 2.01M | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
| Dec 2023 | 0 | 0 | 0 |
Adagene alternative data
| Aug 2023 | 248 |
|---|---|
| Sep 2023 | 248 |
| Oct 2023 | 248 |
| Nov 2023 | 248 |
| Dec 2023 | 248 |
| Jan 2024 | 248 |
| Feb 2024 | 248 |
| Apr 2024 | 248 |
| May 2024 | 174 |
| Jun 2024 | 174 |
| Jul 2024 | 174 |
Adagene other data
4.65%
-3.78%
of ADAG is owned by hedge funds
2.51M
-1.69M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 28 Dec 2021 Issue date: 30 Jun 2022 |
Grant Filling date: 1 Feb 2019 Issue date: 14 Jun 2022 |
Application Filling date: 1 Dec 2021 Issue date: 24 Mar 2022 |
Grant Utility: Anti-CD137 molecules and use thereof Filling date: 21 Aug 2018 Issue date: 8 Feb 2022 |
Application Filling date: 2 Feb 2019 Issue date: 8 Jul 2021 |
Application Filling date: 2 Feb 2019 Issue date: 8 Jul 2021 |
Application Filling date: 29 Mar 2019 Issue date: 29 Apr 2021 |
Application Filling date: 30 Nov 2018 Issue date: 3 Dec 2020 |
Application Filling date: 21 Aug 2018 Issue date: 26 Nov 2020 |
Application Filling date: 21 Aug 2017 Issue date: 19 Nov 2020 |
-
What's the price of Adagene stock today?
One share of Adagene stock can currently be purchased for approximately $1.92.
-
When is Adagene's next earnings date?
Unfortunately, Adagene's (ADAG) next earnings date is currently unknown.
-
Does Adagene pay dividends?
No, Adagene does not pay dividends.
-
How much money does Adagene make?
Adagene has a market capitalization of 84.55M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 94.9% to 18.11M US dollars. Adagene made a loss 18.95M US dollars in net income (profit) last year or -$1.55 on an earnings per share basis.
-
What is Adagene's stock symbol?
Adagene Inc. is traded on the NASDAQ under the ticker symbol "ADAG".
-
What is Adagene's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Adagene?
Shares of Adagene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Adagene have?
As Jul 2024, Adagene employs 174 workers, which is 30% less then previous quarter.
-
When Adagene went public?
Adagene Inc. is publicly traded company for more then 4 years since IPO on 9 Feb 2021.
-
What is Adagene's official website?
The official website for Adagene is adagene.com.
-
How can i contact Adagene?
Adagene can be reached via phone at +86 512 8777 3632.
Adagene company profile:
Adagene Inc.
adagene.comExchange:
NASDAQ
Full time employees:
174
Industry:
Biotechnology
Sector:
Healthcare
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Building C14
Suzhou, 215123
Suzhou, 215123
CIK: 0001818838
ISIN: US0053291078
CUSIP: 005329107
